Sutro Biopharma, Inc.
STRO
$7.30
-$0.72-8.95%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -74.88% | -67.70% | -113.31% | -112.99% | 28.12% |
| Total Depreciation and Amortization | 6.88% | 6.35% | 5.67% | 5.90% | 7.08% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 610.66% | 21.37% | 39.56% | -12.90% | -15.01% |
| Change in Net Operating Assets | -2,418.70% | -693.43% | 161.59% | 125.89% | -54.90% |
| Cash from Operations | -110.47% | -233.08% | -68.75% | -71.61% | 29.30% |
| Capital Expenditure | 25.70% | -6.23% | -0.18% | 28.20% | 44.38% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 4.87% | 248.68% | 4,213.91% | 56,576.73% | 1,020.83% |
| Cash from Investing | 5.85% | 243.76% | 2,000.21% | 5,668.50% | 687.69% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 100.00% | 100.00% | 67.34% | 42.34% |
| Issuance of Common Stock | -99.62% | -98.64% | 3,129.83% | 588.10% | 232.34% |
| Repurchase of Common Stock | 40.41% | 23.87% | 23.73% | -3.88% | 1.02% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -100.00% |
| Cash from Financing | -99.91% | -98.81% | -22.19% | -31.62% | -40.51% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -217.17% | 81.46% | 1,401.72% | 449.75% | 720.48% |